Trial Evaluating the Efficacy of Local Budesonide Therapy in the Management of Hyposmia in COVID-19 Patients Without Signs of Severity

This is a multicenter randomized trial to evaluate the efficacy of local budesonide (nasal irrigation) in the management of persistent hyposmia in COVID-19 patients.

Inclusion criteria

• Patient over 18 years of age;
• Patient with a suspected SARS-CoV-2 infection in a epidemic context, whether or not confirmed by PCR, or contact close to a PCR-confirmed case, typical chest CT scan (unsystematized frosted glass areas predominantly sub-pleural, and at a later stage of alveolar condensation with no excavations neither nodules nor masses) or positive serology ;
• Patient with isolated acute hyposmia persisting at D30. of the onset of signs of CA-MRSA-CoV-2 infection;
• Absence of PCR-confirmed SARS-CoV-2 portage at the time of inclusion

Exclusion criteria

• Known hypersensitivity to budesonide or to any of the excipients of the medicine;
• Hemostasis disorder, or epistaxis;
• Oromo-oral-nasal and ophthalmic herpes virus infection;
• Long-term corticosteroid treatment;
• Treatment with potent CYP3A4 inhibitors (e.g., CYP3A4 inhibitors); ketoconazole, itraconazole, voriconazole, posaconazole, clarithromycin, telithromycin, nefazodone and HIV proteases) ;
• Forms of CoV-2-SARS with respiratory signs or other than anosmia persisting at 30 days from the onset of symptoms;
• Hyposmia persisting for more than 90 days after onset of symptoms;
• Other causes of hyposmia revealed on interrogation or an MRI;